Search Result

Results for "

HCV polymerase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (63) HCV Protease (9) Antibiotic (1) Biochemical Assay Reagents (1) DNA/RNA Synthesis (19) Drug Metabolite (2) Endogenous Metabolite (6) Enterovirus (4) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (2) Reference Standards (4) RSV (2) SARS-CoV (9) Topoisomerase (4) Virus Protease (2)
By Research Areas:	Infection (68) Inflammation/Immunology (1)
Click Chemistry:	Azide (3)
Oligonucleotides:	Nucleosides and their Analogs (3) C (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: HCV HCV Protease PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-101634

ABT-072	HCV	Infection
ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-101634A

ABT-072 potassium trihydrate	HCV	Infection
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-169815

HCV NS5B polymerase-IN-2	Virus Protease HCV	Infection
HCV NS5B polymerase-IN-2 (Compound 298) is a Ns5b polymerase inhibitor. HCV NS5B polymerase-IN-2 is promising for research of hepatitis C virus (HCV) infections .

HY-109047

Adafosbuvir AL-335	HCV DNA/RNA Synthesis	Infection
Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against *HCV* and acts as a potent inhibitor of HCV RNA polymerase .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-13998R

Dasabuvir (Standard) ABT-333 (Standard)	Reference Standards HCV DNA/RNA Synthesis	Infection
Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-114571

cis-Lomibuvir cis-VX-222	DNA/RNA Synthesis HCV	Infection
cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 *HCV* subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis . cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14391

PSI-353661 GS-558093	HCV	Infection
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against *HCV* infection. PSI-353661 shows EC₉₀s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .

HY-150760

GSK5852 GSK2485852	HCV	Inflammation/Immunology
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC₅₀ value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC₅₀s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .

HY-13247

Setrobuvir ANA598	DNA/RNA Synthesis HCV SARS-CoV	Infection
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition .

HY-10544

Tegobuvir 4 Publications Verification GS 333126; GS-9190	HCV	Infection
Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.

HY-10165

PSI-6130 1 Publications Verification R 1656	HCV	Infection
PSI-6130 is a potent and selective inhibitor of **HCV NS5B polymerase*, and inhibits HCV* replication with a mean IC₅₀ of 0.6 μM.

HY-13465

VCH-916 1 Publications Verification	HCV	Infection
VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

HY-145374

AL-611	HCV Protease	Infection
AL-611 is an HCV NS5B polymerase inhibitor (EC₅₀ = 5 nM).

HY-50680

HCVP-IN-1	HCV Protease	Infection
HCVP-IN-1 (compound 1) is a *hepatitis C viral polymerase* (HCVP)** inhibitor .

HY-15591

TMC647055	HCV	Infection
TMC647055 is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 can be used for the research of Hepatitis C virus (HCV) .

HY-18079

BILB 1941	HCV	Infection
BILB 1941 is a potent and specific nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase in vitro .

HY-19558

IDX184	HCV HCV Protease	Infection
IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits **HCV polymerase (IC₅₀=0.31 μM, K_i**=52.3 nM) .

HY-15591A

TMC647055 Choline salt 1 Publications Verification	HCV	Infection
TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV) .

HY-14775

Nesbuvir 5+ Cited Publications HCV-796	HCV	Infection
Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

HY-12634

Deleobuvir BI 207127	HCV	Infection
Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.

HY-169746

Antiviral agent 63	HCV	Infection
Antiviral agent 63 is a nucleoside analog with anti-HCV activity. Antiviral agent 63 can inhibit viral replication by inhibiting the activity of HCV RNA-dependent RNA polymerase or other virus-related enzymes .

HY-124592

BMT-052	HCV	Infection
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 *HCV* subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-172230

Anti-infective agent 10	Virus Protease HCV	Infection
Anti-infective agent 10 (Compound Example 30) is a ns5b polymerase inhibitor that can be used as an anti-HCV agent .

HY-171587

3′-Deoxy CTP	HCV	Infection
3′-Deoxy CTP is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of *HCV* nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .

HY-172428

Encofosbuvir	HCV	Infection
Encofosbuvir is the inhibitor for **HCV NS5B polymerase that inhibits GT1b, GT2a and GT3a with EC₅₀** of 102.4, 82.51 and 46.91 nM. Encofosbuvir inhibits HCV replication and can be used for reseearchs of hepatitis C in mammals .

HY-111204

MK3281	HCV	Infection
MK3281 (Compound 33) is a non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor, with an EC₅₀ of 28 nM for gt1a .

HY-12429

Beclabuvir 4 Publications Verification BMS-791325	HCV	Infection
Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM .

HY-75800R

Lomibuvir (Standard)	DNA/RNA Synthesis HCV	Infection
Lomibuvir (Standard) is the analytical standard of Lomibuvir. This product is intended for research and analytical applications. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-15236

PSI-6206 3 Publications Verification RO 2433; GS-331007	HCV	Infection
PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-12429A

Beclabuvir hydrochloride BMS-791325 hydrochloride	HCV	Infection
Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM .

HY-19921

JTK-853	HCV	Infection
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) *polymerase* inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-10240

Mericitabine 5+ Cited Publications RG 7128; R-7128; PSI 6130 diisobutyrate	HCV	Infection
Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

HY-14775R

Nesbuvir (Standard)	HCV	Infection
Nesbuvir (Standard) is the analytical standard of Nesbuvir. This product is intended for research and analytical applications. Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

HY-171587A

3′-Deoxy CTP trisodium	HCV	Infection
3′-Deoxy CTP trisodium is the sodium salt form of 3′-Deoxy CTP (HY-171587). 3′-Deoxy CTP trisodium is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP trisodium can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of *HCV* nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP trisodium can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .

HY-10468

NM107 1 Publications Verification 2'-C-Methylcytidine	HCV	Infection
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM .

HY-13465A

VCH-916 free base	HCV	Infection
VCH-916 free base is the free base form of VCH-916 (HY-13465). VCH-916 free base is an inhibitor for non-nucleoside type NS5B **HCV polymerase** .

HY-108060A

Valopicitabine dihydrochloride NM283 dihydrochloride	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-108060

Valopicitabine NM283	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-113659

3',5'-O-Bis(isobutiryl)-4'-azido-2'-β-C-methyl-2'-deoxycytidine	Endogenous Metabolite	Infection
3',5'-O-Bis(isobutyryl)-4'-azido-2'-β-C-methyl-2'-deoxycytidine functions as an NS5B inhibitor of RNA polymerase, and is utilized in the treatment of HCV infection.

HY-15236S

PSI-6206-13C,d3 RO-2433-¹³C,d₃; GS-331007-¹³C,d₃; Sofosbuvir metabolite GS-331007-¹³C,d₃	HCV	Infection
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-10240R

Mericitabine (Standard) RG 7128 (Standard); R-7128 (Standard); PSI 6130 diisobutyrate (Standard)	Reference Standards HCV	Infection
Mericitabine (Standard) is the analytical standard of Mericitabine. This product is intended for research and analytical applications. Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine	HCV DNA/RNA Synthesis	Infection
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of *HCV. R-1479 inhibits HCV* replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-135867

NHC-triphosphate	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-114216

DBPR110	Endogenous Metabolite	Infection
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .

HY-15745A

PSI-7409 tetrasodium 5+ Cited Publications	HCV	Infection
PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting **HCV NS5B polymerases, with IC₅₀*s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases*, respectively.

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library

349 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 349 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867

NHC-triphosphate	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867A

NHC-triphosphate tetrasodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

Cat. No.	Compare	Product Name	Species	Source

HY-P703547

	HCVNS5B Protein, HCV Genome polyprotein; Hepatitis C virus genotype 1b (strain HC-J4); HCV; p23; Helicase; Hydrolase; Ion channel; Multifunctional enzyme; Nucleotidyltransferase; Protease; Ribonucleoprotein; RNA-binding; RNA-directed RNA polymerase; Serine protease; Thiol protease; Transferase; Viral ion channel; Viral nucleoprotein	Others	E. coli
	POLG proteins play multiple roles in the viral life cycle, contributing to viral RNA packaging, budding, and particle production. It exhibits RNA-binding and RNA chaperone activities, affecting translation initiation through interactions with viral IRES and ribosomal subunits. HCVNS5B Protein, HCV is the recombinant HCVNS5B, expressed by E. coli, with tag Free labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15236S

PSI-6206-13C,d3
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-124592

BMT-052
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-15236S1

PSI-6206-d1,13C,15N2
PSI-6206-d1, ¹³C, ¹⁵N₂ is ¹⁵N and ¹³C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-W011834S

2'-O-Methylcytidine-d3
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

Cat. No.	Product Name		Classification

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine		Azide
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of *HCV. R-1479 inhibits HCV* replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626		Azide
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride		Azide
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine		Nucleosides and their Analogs C
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of *HCV. R-1479 inhibits HCV* replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W011834

2'-O-Methylcytidine		Nucleosides and their Analogs C
2'-O-Methylcytidine is an orally active 2'-substituted nucleoside as a inhibitor of HCV replication with antiviral activity. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate .

HY-113659

3',5'-O-Bis(isobutiryl)-4'-azido-2'-β-C-methyl-2'-deoxycytidine		Nucleosides and their Analogs C
3',5'-O-Bis(isobutyryl)-4'-azido-2'-β-C-methyl-2'-deoxycytidine functions as an NS5B inhibitor of RNA polymerase, and is utilized in the treatment of HCV infection.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HCV polymerase

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products